Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Oxaliplatin and Capecitabine and Trastuzumab
Oxaliplatin and Capecitabine and Trastuzumab
Routinely available
Local application
02/02/2022
Indication
For palliative treatment of gastro-oesophageal adenocarcinoma with Her-2 over-expression.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local or regional guidance
Formulation
Oxaliplatin for intravenous infusion and Capecitabine oral tablets and Trastuzumab for intravenous infusion
Comments
February 2022 - Routinely available in line with local prescribing guidance. Included on the ERF for Specialist use only.